The immunopathogenesis of paraneoplastic neurological syndromes

Clinical Science

Volumn 102, Issue 5, 2002, Pages 475-486

  Sutton, Ian ^a   Winer, John B ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antibody; Cytotoxic T lymphocyte; Paraneoplastic; Pathogenesis

Indexed keywords

ANTIGEN EXPRESSION; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; MALIGNANT NEOPLASTIC DISEASE; PARANEOPLASTIC NEUROPATHY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW;

AUTOANTIBODIES; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; PARANEOPLASTIC CEREBELLAR DEGENERATION; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM;

EID: 0036260904     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20010121     Document Type: Review

References (89)

1. Primary sensory neuropathy with muscular changes associated with carcinoma
2. Subacute cortical cerebellar degeneration and its relation to carcinoma
3. Carcinomatous neuropathy and myopathy. A clinical and pathological study
4. Neurological syndromes associated with carcinoma. The carcinomatous neuromyopathies
5. Serological findings in carcinomatous neuropathy
6. Immunofluorescent detection of antibodies against neurones in sensory carcinomatous neuropathy
7. The Lambert-Eaton myasthenic syndrome. A review of 50 cases
8. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients
9. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies
10. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome
11. Paraneoplastic autoantibodies: The case for a descriptive generic nomenclature
12. Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): The case for a nomenclature based on antibody and antigen specificity
13. New Purkinje cell antibody (PCA-2): Marker of lung cancer-related neurological autoimmunity
14. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease
15. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients
16. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer
17. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse
18. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome
19. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues
20. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy
21. Immunohistochemical analysis of the immune reaction in the nervous system in paraneoplastic encephalomyelitis
22. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis
23. Ganglionitis in paraneoplastic subacute sensory neuronopathy: A morphologic study
24. RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein
25. Anti-Hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients
26. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer
27. Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration
28. A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues
29. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients
30. Paraneoplastic cerebellar degeneration with anti-Yo antibody in a man
31. Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of unknown origin
32. Anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus
33. Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors
34. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration
35. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration
36. Sub-acute cerebellar degeneration with anti-Yo autoantibodies: Imunohistochemical analysis of the immune reaction in the central nervous system
37. Ultrastructural localization of anti-Purkinje cell antibody-binding sites in paraneoplastic cerebellar degeneration
38. The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: Implications for neuronal and tumor cell survival
39. An antineuronal autoantibody in paraneoplastic opsoclonus
40. Anti-Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer
41. The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia
42. Immunological and pathological study of anti-Ri-associated encephalopathy
43. Anti-Ri associated paraneoplastic opsoclonus-ataxia syndrome in a man with transitional cell carcinoma
44. Chronic progressive paraneoplastic syndrome with prominent brainstem and spinal cord involvement associated with type-2 anti-neuronal nuclear antibodies (ANNA-2) and breast cancer
45. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders
46. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer
47. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins
48. Paraneoplastic brainstem encephalitis in a woman with anti-Ma2 antibody
49. Limbic encephalitis and antibodies to Ma2: A paraneoplastic presentation of breast cancer
50. Paraneoplastic subacute cerebellar degeneration in Hodgkin's disease. Report of three cases and review of the literature
51. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease
52. A reversible neuronal antibody (anti-Tr) associated paraneoplastic cerebellar degeneration in Hodgkin's disease
53. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor
54. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes
55. Intrathecal synthesis of the anti-Hu antibody in patients with paraneoplastic encephalomyelitis or sensory neuronopathy: Clinical-immunologic correlation
56. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome
57. Antibodies to motor nerve terminals: An electrophysiological study of a human myasthenic syndrome transferred to mouse
58. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones
59. Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation
60. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4
61. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel
62. Cerebrospinal fluid findings in cerebellar dysfunction associated with Lambert-Eaton myasthenic syndrome
63. Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice
64. Type IIa ('anti-Hu') antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro
65. Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption
66. Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody
67. Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model
68. Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration
69. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice
70. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice
71. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss
72. Nuclear localization of anti-Hu antibody is not associated with in vitro cytotoxicity
73. Paraneoplastic anti-Hu serum: Studies on human tumor cell lines
74. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis
75. Tumor-specific killer cells in paraneoplastic cerebellar degeneration
76. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration
77. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma
78. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies
79. Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival
80. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice
81. The labyrinthine ways of cancer immunotherapy-T cell, tumor cell encounter: "How do I lose thee? Let me count the ways"
82. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell tung carcinoma
83. Absence of HuD gene mutations in paraneoplastic small cell lung cancer tissue
84. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies
85. Restricted IgG1 subclass of anti-Yo antibodies in paraneoplastic cerebellar degeneration
86. Pattern of epitopic reactivity of the anti-Hu antibody on HuD with and without paraneoplastic syndrome
87. Activated non-neural specific T cells open the blood-brain barrier to circulating antibodies
88. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies